107 related articles for article (PubMed ID: 12675652)
1. No evidence for accumulation of insulin glargine (LANTUS).
Biermann E
Diabet Med; 2003 Apr; 20(4):333-4; author reply 334-5. PubMed ID: 12675652
[No Abstract] [Full Text] [Related]
2. No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes.
Heise T; Bott S; Rave K; Dressler A; Rosskamp R; Heinemann L
Diabet Med; 2002 Jun; 19(6):490-5. PubMed ID: 12060061
[TBL] [Abstract][Full Text] [Related]
3. Insulin detemir (levemir), a new long-acting insulin.
Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
5. Insulin glargine: a long-acting insulin for diabetes mellitus.
Garces K
Issues Emerg Health Technol; 2003 Nov; (52):1-4. PubMed ID: 14626260
[TBL] [Abstract][Full Text] [Related]
6. Twenty-four hour action of insulin glargine (Lantus) may be too short for once-daily dosing: a case report.
Clement S; Bowen-Wright H
Diabetes Care; 2002 Aug; 25(8):1479-80. PubMed ID: 12145255
[No Abstract] [Full Text] [Related]
7. Insulin glargine.
Am J Health Syst Pharm; 2000 Nov; 57(21):1960-1. PubMed ID: 11094649
[No Abstract] [Full Text] [Related]
8. Theoretical pharmacokinetic advantages and methodological flaws: glargine is not superior to NPH insulin in children with type 1 diabetes mellitus.
Dora JM; Scheffel RS
Arq Bras Endocrinol Metabol; 2010 Feb; 54(1):81-3. PubMed ID: 20414553
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes.
Porcellati F; Rossetti P; Ricci NB; Pampanelli S; Torlone E; Campos SH; Andreoli AM; Bolli GB; Fanelli CG
Diabetes Care; 2007 May; 30(5):1261-3. PubMed ID: 17303785
[No Abstract] [Full Text] [Related]
10. Prospective audit of the introduction of insulin glargine (lantus) into clinical practice in type 1 diabetic patients.
Gallen IW; Carter C
Diabetes Care; 2003 Dec; 26(12):3352-3. PubMed ID: 14633830
[No Abstract] [Full Text] [Related]
11. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.
Kuerzel GU; Shukla U; Scholtz HE; Pretorius SG; Wessels DH; Venter C; Potgieter MA; Lang AM; Koose T; Bernhardt E
Curr Med Res Opin; 2003; 19(1):34-40. PubMed ID: 12661778
[TBL] [Abstract][Full Text] [Related]
12. Optimizing insulin regimens in type 1 diabetes. How to help patients get control of their life.
Bohannon NJ
Postgrad Med; 2003 Jun; 113(6):39-42, 45-8, 54. PubMed ID: 12838803
[TBL] [Abstract][Full Text] [Related]
13. Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes.
Peter R; Luzio SD; Dunseath G; Miles A; Hare B; Backx K; Pauvaday V; Owens DR
Diabetes Care; 2005 Mar; 28(3):560-5. PubMed ID: 15735188
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study: response to Porcellati et al.
Banarer S
Diabetes Care; 2008 Mar; 31(3):e16; author reply e17. PubMed ID: 18308679
[No Abstract] [Full Text] [Related]
15. Insulin glargine: a new basal insulin analogue.
Younis N; Soran H; Bowen-Jones D
QJM; 2002 Nov; 95(11):757-61. PubMed ID: 12391389
[No Abstract] [Full Text] [Related]
16. [Clinical experiences with Lantus therapy in Swedish routine health care].
Löndahl M; Nilsson A; Katzman P
Lakartidningen; 2005 Sep 5-11; 102(36):2503, 2505. PubMed ID: 16196437
[No Abstract] [Full Text] [Related]
17. Use of insulin glargine during embryogenesis in a pregnant woman with Type 1 diabetes.
Holstein A; Plaschke A; Egberts EH
Diabet Med; 2003 Sep; 20(9):779-80. PubMed ID: 12925063
[No Abstract] [Full Text] [Related]
18. Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes.
Xu P; Ye X; Zhang Y; Yuan Q; Liu M; Wu Q; Ren G; Li D
J Diabetes Complications; 2015; 29(1):5-12. PubMed ID: 25456819
[TBL] [Abstract][Full Text] [Related]
19. Reducing mistakes in patient administration of glargine and lispro.
Schutta MH
Diabetes Care; 2002 Jun; 25(6):1098-9. PubMed ID: 12032124
[No Abstract] [Full Text] [Related]
20. In Brief: Semglee - a new insulin glargine for diabetes.
Med Lett Drugs Ther; 2021 Jan; 63(1616):14-15. PubMed ID: 33512347
[No Abstract] [Full Text] [Related]
[Next] [New Search]
